Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Accumulated Expenses (2024 - 2025)

Quantum Biopharma's Accumulated Expenses history spans 2 years, with the latest figure at $2.2 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 98.71% to $2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 million, a 98.71% increase, with the full-year FY2025 number at $2.2 million, up 98.71% from a year prior.
  • Accumulated Expenses hit $2.2 million in Q4 2025 for Quantum Biopharma, up from $1.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for QNTM hit a ceiling of $2.2 million in Q4 2025 and a floor of $1.1 million in Q4 2024.